Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and SI-Bone (SIBN)
10:08am, Tuesday, 10'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioxcel Therapeutics (BTAI) and SI-Bone (SIBN) with bullish
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (NASDAQ: BTAI) and SI-Bone (NASDAQ: SIBN)
10:08am, Tuesday, 10'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioxcel Therapeutics (
BTAI
–
Research Report
) and SI-Bone (
SIBN
–
Research Report
) with bullish
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
11:00am, Monday, 09'th Mar 2020
Key BXCL501 data readouts expected in mid-2020 – including results from the SERENITY program and the Phase 1b/2 TRANQUILITY trial in geriatric dementia Strengthened balance.
BioXcel Therapeutics, Inc. to Host Earnings Call
10:00am, Monday, 09'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 9, 2020 / BioXcel Therapeutics, Inc. (BTAI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 9, 2020 at 8:30 A
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
08:14pm, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccin
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
12:00am, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
Ignore the Coronavirus Panic and Stop Selling
05:11pm, Tuesday, 03'rd Mar 2020
Unsurprisingly, the mainstream media has it all wrong. The coronavirus isn't the end of the world. Stop selling and start profiting now.
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast
12:00pm, Monday, 02'nd Mar 2020
NEW HAVEN, Conn., March 02, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
BYND, ALC among premarket gainers
02:13pm, Wednesday, 26'th Feb 2020
SELLAS Life Sciences Group (NASDAQ:SLS) +23% on positive follow-up phase 1/2 clinical data for Galinpepimut-S in acute myeloid leukemia.Alcon (NYSE:ALC) +10% on Q4 results.Moderna (NASDAQ:MRNA) +9%�
BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
12:00pm, Wednesday, 26'th Feb 2020
NEW HAVEN, Conn., Feb. 26, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
3 Biotech Stocks That Surged Last Week
11:21am, Monday, 24'th Feb 2020
See if they can keep climbing.
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA)
11:17am, Friday, 21'st Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA)
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA)
11:17am, Friday, 21'st Feb 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (
BTAI
–
Research Report
), Atara Biotherapeutics (
ATRA
–
Research Report
) a
VIAC, WIX among premarket losers
02:17pm, Thursday, 20'th Feb 2020
Tivity Health (NASDAQ:TVTY) -39% on Q4 earnings.Six Flags Entertainment (NYSE:SIX) -18% on Q4 earnings.BioXcel Therapeutics (NASDAQ:BTAI) -17% after pricing equity offering.Axovant Gene Therapie
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
12:30pm, Thursday, 20'th Feb 2020
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 2,000,000
